This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis
Scientific Reports Open Access 16 June 2023
-
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
Experimental Hematology & Oncology Open Access 06 August 2019
-
Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
Journal of Hematology & Oncology Open Access 29 May 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Accession codes
References
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88–92.
Duhren-von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012; 489: 309–312.
Gobessi S, Laurenti L, Longo PG, Carsetti L, Berno V, Sica S et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009; 23: 686–697.
Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010; 115: 4497–4506.
Herman SE, Barr PM, McAuley EM, Liu D, Wiestner A, Friedberg JW . Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia 2013; 27: 1769–1773.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32–42.
Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 2013; e-pub ahead of print 25 November 2013; doi:10.1038/leu.2013.358.
Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603–3612.
Kharfan-Dabaja MA, Wierda WG, Cooper LJN . Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia 2013; e-pub ahead of print 25 October 2013; doi:10.1038/leu.2013.311.
Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J . Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed 2011; 16: 277–306.
Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078–2088.
Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 2013; 23: 826–838.
Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009; 139: 573–586.
Acknowledgements
This work was supported by the National Science Center grant 2012/07/B/NZ6/03498 (MW), the Polish Ministry of Science and Higher Education grant IP2011 060271 (MW), the European Commission 7th Framework Programme: FP7-REGPOT-2012-CT2012-316254-BASTION (JG), and the Medical University of Warsaw grant 1M19/PM12D/13 (KB).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Bojarczuk, K., Siernicka, M., Dwojak, M. et al. B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leukemia 28, 1163–1167 (2014). https://doi.org/10.1038/leu.2014.12
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.12
This article is cited by
-
Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis
Scientific Reports (2023)
-
Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies
Current Oncology Reports (2022)
-
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
Experimental Hematology & Oncology (2019)
-
New roles for B cell receptor associated kinases: when the B cell is not the target
Leukemia (2019)
-
Current Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies
Drugs & Aging (2017)